Epstein Secrets

From: Boris Nikolic To: Jeffrey Epstein <jeevacation(ggmail.com> Subject: FW: AAVL Date: Fri, 14 Aug 2015 15:01:38 +0000 Attachments: disclaim.txt Inline-Images: image001.gif I did not

From: Boris Nikolic To: Jeffrey Epstein <jeevacation(ggmail.com> Subject: FW: AAVL Date

From: Boris Nikolic To: Jeffrey Epstein <jeevacation(ggmail.com> Subject: FW: AA

uncing post-mkt yday plans to scrap a planned Phase 2b trial and instead initiate added preclinical studies to investigate optimal dose, delivery of AVA-101 and AVA-201 in wet age-related macular degeneration (wet AMD). * "Investors need a clear path forward" before getting back in AAVL, Cowen analyst

From: Vahe Stepanian To: Jeffrey Epstein <[email protected]> Morris Stewart Oldfield , Richard Kahn , Ariane Dwyer , Paul CC: Daniel Sabba Subject: AAVL: (BN) Avalanche Drops as G

ps as Gene Therapy Trial Miss High Expectation [C] Date: Tue, 16 Jun 2015 14:02:02 +0000 Inline-Images: image002.jpg Classification: Confidential Jeffrey — we are following up with the below news regarding AAVL. The stock is trading down $19.11 to $19.7657 per the Bloomberg screenshot below. Please l

From: Vahe Stepanian To: Jeffrey Epstein <[email protected]> Morris Stewart Oldfield

ns from another drug. After the company released trial data Monday, shares fell as much as 32 percent to $26.40 in late trading. The study assessed AVA-101's safety for patients with the disease, called wet age-related macular degeneration or wet AMD. Although the study wasn't designed to show statistic

From: Boris Nikolic Sent: Friday, August 14, 2015 3:02 PM To: Jeffrey Epstein Subject: FW: AAVL Attachments: disclaim.txt I did not sell a share yet. Will keep and seat on it. The price per share is less what they have o

t: Friday, August 14, 2015 3:02 PM To: Jeffrey Epstein Subject: FW: AAVL Attachments: disclaim.txt

lic Sent: Friday, August 14, 2015 3:02 PM To: Jeffrey Epstein Subject: FW: AAVL Attachments: discla

uncing post-mkt yday plans =o scrap a planned Phase 2b trial and instead initiate added preclinical st=dies to investigate optimal dose, delivery of AVA-101 and AVA-201 in wet age-related macular degeneration (wet AMD). • "Investors need a clear path forward=94 before getting back in AAVL, Cowen analys

From: Vahe Stepaniar To: "jeffrey E." <[email protected]> CC: Daniel Sabba , Aria

Bio Falls After Scrapping Plans for Ph.2b Study [C] Date: Fri, 14 Aug 2015 14:32:36 +0000 Wine-Images: image003.jpg Classification: Confidential Jeffrey - posting you on AAVL. The stock is down -25% today to $10.289 on the back of news that it plans to scrap a planned Phase 2b trial — additional deta

erg) -- Avalanche Biotechnologies said it won't initiate Phase 2b trial in 2H of 2015 after further analyses of previously reported Phase 2a data of AVA-101 for potential treatment of wet age-related macular degeneration. AAVL down 20% post-mkt after 112k shrs traded. * AAVL instead will run added precl